$PIII
P3 Health Partners Inc. Stock $piii

$piii Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000162828024013625 Filed on March 28, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$346.9M	$1.266B	$258.2M
YoY Change	34.33%	20.67%	339.42%
Cost Of Revenue	$367.7M	$1.235B	$269.2M
YoY Change	36.59%	16.79%	34.52%
Gross Profit	-$20.82M	$31.64M	-$10.97M
YoY Change	89.85%	-508.04%	-50.71%
Gross Profit Margin	-6.0%	2.5%	-4.25%
Selling, General & Admin	$25.15M	$125.6M	$41.43M
YoY Change	-39.29%	-22.65%	138.81%
% of Gross Profit		397.01%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$21.63M	$86.68M	$22.00M
YoY Change	-1.67%	3511.46%	11630.92%
% of Gross Profit		273.98%
Operating Expenses	$43.44M	$199.6M	$62.08M
YoY Change	-30.03%	-92.35%	-47.23%
Operating Profit	-$64.26M	-$167.9M	-$73.05M
YoY Change	-12.03%	-89.24%	24.05%
Interest Expense	-$4.046M	-$15.99M	-$3.159M
YoY Change	28.07%	40.17%	-248.23%
% of Operating Profit
Other Income/Expense, Net	$966.0K	$184.0K	$9.236M
YoY Change	-89.54%	-84.89%	872.44%
Pretax Income	-$67.34M	-$183.7M	-$530.5M
YoY Change	-87.31%	-88.22%	815.58%
Income Tax	$1.767M	$2.695M	$1.862M
% Of Pretax Income
Net Earnings	-$25.46M	-$57.77M	-$94.03M
YoY Change	-72.92%	-78.61%	832.69%
Net Earnings / Revenue	-7.34%	-4.56%	-36.41%
Basic Earnings Per Share		-$0.61
Diluted Earnings Per Share	-$0.22	-$0.61	-$2.26
COMMON SHARES
Basic Shares Outstanding		94.89M shares
Diluted Shares Outstanding		294.6M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.32M	$36.32M	$17.54M
YoY Change	107.1%	107.1%	-87.52%
Cash & Equivalents	$36.30M		$17.54M
Short-Term Investments
Other Short-Term Assets	$8.227M	$8.227M	$3.563M
YoY Change	130.9%	130.9%	-51.29%
Inventory
Prepaid Expenses
Receivables	$118.5M	$118.5M	$72.91M
Other Receivables	$2.973M	$2.973M	$6.678M
Total Short-Term Assets	$166.0M	$166.0M	$100.7M
YoY Change	64.88%	64.88%	-49.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.686M	$8.686M	$8.839M
YoY Change	-1.73%	-1.73%	9.83%
Goodwill			$0.00
YoY Change			-100.0%
Intangibles	$666.7M		$751.1M
YoY Change	-11.23%		-10.14%
Long-Term Investments
YoY Change
Other Assets	$19.53M	$19.53M	$15.99M
YoY Change	22.15%	22.15%	50.69%
Total Long-Term Assets	$695.0M	$695.0M	$775.9M
YoY Change	-10.43%	-10.43%	-64.15%
TOTAL ASSETS
Total Short-Term Assets	$166.0M	$166.0M	$100.7M
Total Long-Term Assets	$695.0M	$695.0M	$775.9M
Total Assets	$861.0M	$861.0M	$876.6M
YoY Change	-1.78%	-1.78%	-62.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$219.0M	$219.0M	$11.54M
YoY Change	1797.11%	25.3%	-90.73%
Accrued Expenses	$80.41M	$80.41M	$66.91M
YoY Change	20.18%	20.18%	26.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$299.4M	$299.4M	$241.7M
YoY Change	23.88%	23.88%	21.58%
LONG-TERM LIABILITIES
Long-Term Debt	$108.3M	$108.3M	$94.42M
YoY Change	14.72%	14.72%	18.03%
Other Long-Term Liabilities	$19.61M	$19.61M	$17.83M
YoY Change	10.02%	10.02%	-15.78%
Total Long-Term Liabilities	$127.9M	$127.9M	$112.2M
YoY Change	13.97%	13.97%	10.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$299.4M	$299.4M	$241.7M
Total Long-Term Liabilities	$127.9M	$127.9M	$112.2M
Total Liabilities	$718.8M	$718.8M	$353.9M
YoY Change	103.11%	-17.44%	17.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$367.3M		-$309.5M
YoY Change	18.67%		685.29%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$142.1M	$142.1M	$5.854M
YoY Change
Total Liabilities & Shareholders Equity	$861.0M	$861.0M	$876.6M
YoY Change	-1.78%	-1.78%	-62.92%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$25.46M	-$57.77M	-$94.03M
YoY Change	-72.92%	-78.61%	832.69%
Depreciation, Depletion And Amortization	$21.63M	$86.68M	$22.00M
YoY Change	-1.67%	3511.46%	11630.92%
Cash From Operating Activities	-$15.88M	-$76.03M	-$31.95M
YoY Change	-50.31%	-39.67%	108.28%
INVESTING ACTIVITIES
Capital Expenditures	-$213.0K	$1.827M	-$50.40K
YoY Change	322.62%	-18.18%	-141.81%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$130.00
YoY Change	-100.0%	-100.0%	-100.0%
Cash From Investing Activities	$213.0K	-$1.827M	$50.54K
YoY Change	321.45%	-76.37%	-100.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$645.0K	$86.60M
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	-838.0K	100.3M	15.00M
YoY Change	-105.59%	782.04%	-92.45%
NET CHANGE
Cash From Operating Activities	-15.88M	-76.03M	-31.95M
Cash From Investing Activities	213.0K	-1.827M	50.54K
Cash From Financing Activities	-838.0K	100.3M	15.00M
Net Change In Cash	-16.50M	22.48M	-16.90M
YoY Change	-2.37%	-117.84%	-112.48%
FREE CASH FLOW
Cash From Operating Activities	-$15.88M	-$76.03M	-$31.95M
Capital Expenditures	-$213.0K	$1.827M	-$50.40K
Free Cash Flow	-$15.67M	-$77.86M	-$31.90M
YoY Change	-50.9%	-39.3%	106.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-12705000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1561600000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001832511
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Accounts Payable Noncurrent Related Party Type Extensible Enumeration AccountsPayableNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2022Q4	us-gaap	Accounts Payable Noncurrent Related Party Type Extensible Enumeration AccountsPayableNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40033
CY2023	dei	Entity Registrant Name EntityRegistrantName	P3 Health Partners Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2992794
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2370 Corporate Circle Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89074
CY2023	dei	City Area Code CityAreaCode	702
CY2023	dei	Local Phone Number LocalPhoneNumber	910-3950
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	116900000	usd
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	Las Vegas, Nevada
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36320000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17537000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	4614000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	920000	usd
CY2023Q4	piii	Health Plan Settlement Receivables Allowance For Credit Loss Current HealthPlanSettlementReceivablesAllowanceForCreditLossCurrent	150000	usd
CY2022Q4	piii	Health Plan Settlement Receivables Allowance For Credit Loss Current HealthPlanSettlementReceivablesAllowanceForCreditLossCurrent	0	usd
CY2023Q4	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	118497000	usd
CY2022Q4	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	72092000	usd
CY2023Q4	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	2973000	usd
CY2022Q4	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	7500000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3613000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2643000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	166017000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	100692000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8686000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8839000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	666733000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	751050000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19531000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15990000	usd
CY2023Q4	us-gaap	Assets Assets	860967000	usd
CY2022Q4	us-gaap	Assets Assets	876571000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8663000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11542000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36884000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16647000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3506000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8224000	usd
CY2023Q4	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	34992000	usd
CY2022Q4	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	13608000	usd
CY2023Q4	piii	Claims Payable Current ClaimsPayableCurrent	178009000	usd
CY2022Q4	piii	Claims Payable Current ClaimsPayableCurrent	151207000	usd
CY2023Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	13670000	usd
CY2022Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	26375000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	23648000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	14061000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	299372000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	241664000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13622000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11516000	usd
CY2023Q4	piii	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	1085000	usd
CY2022Q4	piii	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	1517000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4907000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4794000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108319000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	94421000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	427305000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	353912000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	291532000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	516805000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	509442000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	315375000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-367344000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-309545000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	142130000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5854000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	860967000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	876571000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	122362000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	157284000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3233000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5096000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86675000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	87289000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1314952000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1434305000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2610384000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-167930000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1560913000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-15985000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-11404000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-433000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9865000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-249000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2757000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15801000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1218000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-183731000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1559695000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2695000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1862000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-186426000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1561557000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-128653000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1291430000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-57773000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-270127000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.50
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.50
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94889000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41579000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294590000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41579000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	273552000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1786000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	643000	usd
CY2022	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-270127000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86583000	usd
CY2023	piii	Stock Issued During At The Market Sales Net Of Commission And Costs StockIssuedDuringAtTheMarketSalesNetOfCommissionAndCosts	33000	usd
CY2023	piii	Stock Issued During The Period Settlement Of Restricted Stock Units Net Of Shares Withheld For Tax Value StockIssuedDuringThePeriodSettlementOfRestrictedStockUnitsNetOfSharesWithheldForTaxValue	-16000	usd
CY2023	piii	Restricted Stock Units Transaction Bonus RestrictedStockUnitsTransactionBonus	5000000	usd
CY2023	piii	Stock Issued Value Stock Compensation Awards Vesting StockIssuedValueStockCompensationAwardsVesting	0	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5194000	usd
CY2023	piii	Adjustment To Equity Remeasurement Adjustment AdjustmentToEquityRemeasurementAdjustment	117860000	usd
CY2023	piii	Adjustments To Additional Paid In Capital Fair Value Adjustment Redeemable Non Controlling Interest AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNonControllingInterest	-20579000	usd
CY2023	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-57773000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	142130000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-186426000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1561557000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86675000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	87289000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5979000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	19404000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1314952000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	472000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	113000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	400000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-433000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9865000	usd
CY2023	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-12705000	usd
CY2022	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-11461000	usd
CY2023	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	46555000	usd
CY2022	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	21841000	usd
CY2023	piii	Increase Decrease In Clinic Fees Insurance And Other Receivables IncreaseDecreaseInClinicFeesInsuranceAndOtherReceivables	-4560000	usd
CY2022	piii	Increase Decrease In Clinic Fees Insurance And Other Receivables IncreaseDecreaseInClinicFeesInsuranceAndOtherReceivables	5338000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1243000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4266000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	58000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-100000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15988000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6082000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	282000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1920000	usd
CY2023	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	21384000	usd
CY2022	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	-8941000	usd
CY2023	piii	Increase Decrease In Claims Payable IncreaseDecreaseInClaimsPayable	26802000	usd
CY2022	piii	Increase Decrease In Claims Payable IncreaseDecreaseInClaimsPayable	49249000	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	9587000	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	5290000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-450000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4032000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76028000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-126019000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1827000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2233000	usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	5500000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1827000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7733000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	14101000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	173000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	86595000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2023	piii	Deferred Offering Costs Paid DeferredOfferingCostsPaid	175000	usd
CY2022	piii	Deferred Offering Costs Paid DeferredOfferingCostsPaid	0	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3625000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100332000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11375000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22477000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-122377000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18457000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140834000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40934000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18457000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	5813000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5714000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	567000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7222000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6839000	usd
CY2023	piii	Increase In Accrued Expenses Related To Debt Issuance Costs And Original Issue Discount IncreaseInAccruedExpensesRelatedToDebtIssuanceCostsAndOriginalIssueDiscount	212000	usd
CY2022	piii	Increase In Accrued Expenses Related To Debt Issuance Costs And Original Issue Discount IncreaseInAccruedExpensesRelatedToDebtIssuanceCostsAndOriginalIssueDiscount	525000	usd
CY2023	piii	Increase In Accounts Payable Related To Private Placement Offering Costs IncreaseInAccountsPayableRelatedToPrivatePlacementOfferingCosts	12000	usd
CY2022	piii	Increase In Accounts Payable Related To Private Placement Offering Costs IncreaseInAccountsPayableRelatedToPrivatePlacementOfferingCosts	0	usd
CY2023	piii	Increase In Accounts Payable Related To At The Market Offering Costs IncreaseInAccountsPayableRelatedToAtTheMarketOfferingCosts	19000	usd
CY2022	piii	Increase In Accounts Payable Related To At The Market Offering Costs IncreaseInAccountsPayableRelatedToAtTheMarketOfferingCosts	0	usd
CY2023	piii	Increase In Accrued Expenses Related To Atm Offering Costs IncreaseInAccruedExpensesRelatedToATMOfferingCosts	206000	usd
CY2022	piii	Increase In Accrued Expenses Related To Atm Offering Costs IncreaseInAccruedExpensesRelatedToATMOfferingCosts	0	usd
CY2023	piii	Increase In Other Receivable Related To At The Market Sales IncreaseInOtherReceivableRelatedToAtTheMarketSales	33000	usd
CY2022	piii	Increase In Other Receivable Related To At The Market Sales IncreaseInOtherReceivableRelatedToAtTheMarketSales	0	usd
CY2023	piii	Rsu Transaction Bonus RSUTransactionBonus	5000000	usd
CY2022	piii	Rsu Transaction Bonus RSUTransactionBonus	0	usd
CY2023	piii	Remeasurement Adjustment To Redeemable Noncontrolling Interest Resulting From Ownership Changes RemeasurementAdjustmentToRedeemableNoncontrollingInterestResultingFromOwnershipChanges	-117860000	usd
CY2022	piii	Remeasurement Adjustment To Redeemable Noncontrolling Interest Resulting From Ownership Changes RemeasurementAdjustmentToRedeemableNoncontrollingInterestResultingFromOwnershipChanges	0	usd
CY2023	piii	Fair Value Adjustment To Redeemable Noncontrolling Interest FairValueAdjustmentToRedeemableNoncontrollingInterest	20579000	usd
CY2022	piii	Fair Value Adjustment To Redeemable Noncontrolling Interest FairValueAdjustmentToRedeemableNoncontrollingInterest	0	usd
CY2023	piii	Debt Issuance Warrant Issued DebtIssuanceWarrantIssued	0	usd
CY2022	piii	Debt Issuance Warrant Issued DebtIssuanceWarrantIssued	643000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36320000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17537000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	4614000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	920000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40934000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18457000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-186400000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36300000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17500000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that could affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to allowance for credit losses, revenue recognition, the liability for unpaid claims, equity-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles), fair value of liability classified instruments, and judgments related to deferred income taxes. The Company bases its estimates on the best information available at the time, its experiences, and various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36300000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17500000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	4600000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	900000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1266375000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1049471000	usd
CY2023	piii	Premium Risk Adjustment PremiumRiskAdjustment	20300000	usd
CY2022	piii	Premium Risk Adjustment PremiumRiskAdjustment	3300000	usd
CY2023	piii	Health Plans Term Of Contract HealthPlansTermOfContract	P1M
CY2022Q4	piii	Major Customers Number MajorCustomersNumber	3	customer
CY2023Q4	piii	Major Customers Number MajorCustomersNumber	3	customer
CY2023Q4	piii	Patient Fees Receivable Current PatientFeesReceivableCurrent	700000	usd
CY2022Q4	piii	Patient Fees Receivable Current PatientFeesReceivableCurrent	800000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3900000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3500000	usd
CY2022	piii	Capitalized Computer Software Placed Into Service CapitalizedComputerSoftwarePlacedIntoService	700000	usd
CY2023	piii	Capitalized Computer Software Placed Into Service CapitalizedComputerSoftwarePlacedIntoService	0	usd
CY2023Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	13700000	usd
CY2022Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	26400000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	3200000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	4500000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the accompanying consolidated financial statements and accompanying notes have been reclassified to be consistent with the current period presentation. These reclassifications had no impact on the Company’s financial condition, results of operations, or net cash flows.</span></div>
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	40000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13467000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11460000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4781000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2621000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8686000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8839000	usd
CY2023	us-gaap	Depreciation Depreciation	2300000	usd
CY2022	us-gaap	Depreciation Depreciation	2400000	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	1309750000	usd
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1309750000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	5202000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1314952000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	1314952000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	1314952000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	851500000	usd
CY2022Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	463500000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	842835000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	176102000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	666733000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	666733000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	842835000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	91785000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	751050000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84300000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84800000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	84200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	84200000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	109102000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	95000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	84200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	84200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	84200000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	81900000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11200000	shares
CY2023	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in the liability for claims payable was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#79232e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#79232e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#79232e;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Claims unpaid, beginning of period</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151,207 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,958 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incurred, related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,064,341 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">942,570 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period(s)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total incurred</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061,724 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">943,452 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paid, related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">893,092 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">794,026 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period(s)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total paid</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,034,922 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">894,203 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Claims unpaid, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178,009 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151,207 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	151207000	usd
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	101958000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	1064341000	usd
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	942570000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-2617000	usd
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	882000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	1061724000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	943452000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	893092000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	794026000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	141830000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	100177000	usd
CY2023	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	1034922000	usd
CY2022	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	894203000	usd
CY2023Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	178009000	usd
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	151207000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	783000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	579000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108319000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	108319000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	94421000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	94421000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	65000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	44102000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	109102000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	783000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	108319000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-183731000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1559695000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-183731000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1559695000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	170000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	111000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2525000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1751000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2695000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1862000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2695000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1862000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-38584000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-327536000	usd
CY2023	piii	Effective Income Tax Rate Reconciliation Noncontrolling Interest Income Loss And Not Taxable Income Amount EffectiveIncomeTaxRateReconciliationNoncontrollingInterestIncomeLossAndNotTaxableIncomeAmount	-24486000	usd
CY2022	piii	Effective Income Tax Rate Reconciliation Noncontrolling Interest Income Loss And Not Taxable Income Amount EffectiveIncomeTaxRateReconciliationNoncontrollingInterestIncomeLossAndNotTaxableIncomeAmount	-260020000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29781000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	33961000	usd
CY2023	piii	Effective Income Tax Rate Reconciliation Business Acquisition EffectiveIncomeTaxRateReconciliationBusinessAcquisition	-20420000	usd
CY2022	piii	Effective Income Tax Rate Reconciliation Business Acquisition EffectiveIncomeTaxRateReconciliationBusinessAcquisition	35147000	usd
CY2023	piii	Income Tax Rate Reconciliation Return To Provision Amount IncomeTaxRateReconciliationReturnToProvisionAmount	4134000	usd
CY2022	piii	Income Tax Rate Reconciliation Return To Provision Amount IncomeTaxRateReconciliationReturnToProvisionAmount	0	usd
CY2023	piii	Effective Income Tax Rate Reconciliation Deferred Tax Adjustment Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount	1754000	usd
CY2022	piii	Effective Income Tax Rate Reconciliation Deferred Tax Adjustment Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1544000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	270000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2695000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1862000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.015
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2023Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	19709000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	20684000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21525000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17601000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	221000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2764000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1923000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	589000	usd
CY2023Q4	piii	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	3031000	usd
CY2022Q4	piii	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	1995000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	632000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	94000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47041000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43727000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46370000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43558000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	671000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	169000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	338000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	19000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	333000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	150000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	671000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	169000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	13000000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	piii	Maximum Amount Of Shares Owned By Related Party MaximumAmountOfSharesOwnedByRelatedParty	0.4999
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294590000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41579000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	92610000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	216622000	shares
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15300000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11700000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.117
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4625000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4084000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3549000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3211000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3007000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5244000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23720000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7375000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16345000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2700000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1600000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	4204000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3339000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1200000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	800000	usd
CY2023	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	20600000	usd
CY2022	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	0	usd
CY2023	piii	Common Units Exchanged Or Redeemed In Period CommonUnitsExchangedOrRedeemedInPeriod	5400000	shares
CY2022	piii	Common Units Exchanged Or Redeemed In Period CommonUnitsExchangedOrRedeemedInPeriod	0	shares
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	piii	Number Of Health Plans Resulting In Renegotiation NumberOfHealthPlansResultingInRenegotiation	1	plan
CY2022Q4	piii	Related Party Number Of Entity Directors Holding Equity In Related Party RelatedPartyNumberOfEntityDirectorsHoldingEquityInRelatedParty	2	director
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-013625-index-headers.html	Edgar Link	pending
0001628280-24-013625-index.html	Edgar Link	pending
0001628280-24-013625.txt	Edgar Link	pending
0001628280-24-013625-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
piii-20231231.htm	Edgar Link	pending
piii-20231231.xsd	Edgar Link	pending
piii-20231231xex1031.htm	Edgar Link	pending
piii-20231231xex211.htm	Edgar Link	pending
piii-20231231xex231.htm	Edgar Link	pending
piii-20231231xex311.htm	Edgar Link	pending
piii-20231231xex312.htm	Edgar Link	pending
piii-20231231xex321.htm	Edgar Link	pending
piii-20231231xex322.htm	Edgar Link	pending
piii-20231231xex971.htm	Edgar Link	pending
piii-20231231_g1.jpg	Edgar Link	pending
piii-20231231_g2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
piii-20231231_cal.xml	Edgar Link	unprocessable
piii-20231231_lab.xml	Edgar Link	unprocessable
piii-20231231_pre.xml	Edgar Link	unprocessable
piii-20231231_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
piii-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIII
P3 Health Partners Inc. Stock $piii

2023 Q4 Form 10-K Financial Statement

#000162828024013625 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII P3 Health Partners Inc. Stock $piii

2023 Q4 Form 10-K Financial Statement

#000162828024013625 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII
P3 Health Partners Inc. Stock $piii